Spadin
unknown riskAlso: TREK-1 antagonist · Propeptide PE4
Spadin is a naturally occurring peptide derived from the sortilin propeptide that acts as an antagonist of TREK-1 potassium channels. Demonstrates rapid antidepressant effects in animal models (within days vs. weeks for SSRIs). Novel mechanism of action with no current human trials.
Reported Benefits
Antidepressant
Mice: rapid antidepressant-like behavior within 4 days — faster onset than SSRIs. No human data.
Mechanism of Action
Antagonizes TREK-1 (TWIK-related K+ channel 1); increases serotonergic and noradrenergic tone; hippocampal neurogenesis increase in animal models.
Rapid Onset: The Key Claim
The major pharmaceutical problem with current antidepressants is 2–6 week onset to effect. Spadin animal data shows behavioral improvement within 4 days via a completely different mechanism (K+ channel blockade). If this translates to humans, it could address a significant unmet need.
Human trials are the critical missing piece.
✦ Sponsored
Stop Guessing About Your Health. Start Optimizing It.
Advanced diagnostics and licensed medical providers delivering personalized longevity care to uncover root causes, optimize health, and track progress virtually or in person.
Learn More →
Regulatory Status
Research OnlySafety Profile
Side Effects
- •Unknown in humans
Contraindications
- •Insufficient data
Primary Uses
Planning a protocol?
Use the AI Stack Builder to generate a phased schedule, compatibility analysis, and monitoring checklist.
Weekly Briefing
Regulatory updates + new study breakdowns.
For Practitioners
Do you prescribe Spadin?
Get in front of patients who've already researched this protocol and are ready to consult. Featured listings from $199/mo.
Get Listed →